Progress in the treatment of triple negative breast cancer with sacituzumab govitecan

doi:10.3760/cma.j.cn371439-20220715-00123

Abstract

Abstract:

Triple-negative breast cancer is a subtype of invasive breast cancer， accounting for about 15% of all breast cancers. Its clinical treatment is relatively difficult， prone to recurrence and metastasis， with a short median survival and poor prognosis. Sacituzumab govitecan is the first approved antigen-coupled drug targeting trophoblast surface antigen 2 in the world. It has significant clinical efficacy， high safety and less adverse reactions， which brings new hope to the treatment of triple-negative breast cancer.

Key words: Triple negative breast neoplasms, Clinical study, Sacituzumab govitecan

Wang Mengchao, Chen Liwei, Kong Fanming. Progress in the treatment of triple negative breast cancer with sacituzumab govitecan[J]. Journal of International Oncology, 2022, 49(10): 619-622.

References 32

[1]	王佳荔. 分子分型与基因组分析推动难治性转移性三阴性乳腺癌的精准治疗: FUTURE试验[J]. 国际肿瘤学杂志, 2021, 48(11): 698-701. DOI: 10.3760/cma.j.cn371439-20210429-00138. doi: 10.3760/cma.j.cn371439-20210429-00138
[2]	Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61. DOI: 10.1186/s13058-020-01296-5. doi: 10.1186/s13058-020-01296-5 pmid: 32517735
[3]	Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes[J]. NPJ Breast Cancer, 2022, 8(1): 47. DOI: 10.1038/s41523-022-00411-3. doi: 10.1038/s41523-022-00411-3 pmid: 35396508
[4]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. doi: 10.1016/S0140-6736(20)32531-9 pmid: 33278935
[5]	张喆, 贾立周, 唐奇, 等. TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究[J]. 南京医科大学学报(自然科学版), 2019, 39(10): 1453-1458, 1471. DOI: 10.7655/NYDXBNS20191009. doi: 10.7655/NYDXBNS20191009
[6]	U.S. Food & Drug. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer[EB/OL]. [2021-04-08] [2022-09-22]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer.
[7]	孙正魁, 江泽飞. 2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J]. 中国肿瘤外科杂志, 2022, 14(3): 212-218. DOI: 10.3969/j.issn.1674-4136.2022.03.002. doi: 10.3969/j.issn.1674-4136.2022.03.002
[8]	国家药品监督管理局. 2022年6月10日药品批准证明文件待领取信息发布[EB/OL]. [2022-06-10] [2022-09-06]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220610083017154.html.
[9]	云顶新耀. 云顶新耀与吉利德科学联合公布在中国转移性三阴性乳腺癌患者中开展的戈沙妥珠单抗2b期研究达到总体缓解率的主要终点[EB/OL]. [2021-11-11] [2022-09-06]. https://www.everestmedicines.com/CN/News_detail.aspx?nid=432.
[10]	Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751. DOI: 10.1056/NEJMoa1814213. doi: 10.1056/NEJMoa1814213
[11]	Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI: 10.1056/NEJMoa2028485. doi: 10.1056/NEJMoa2028485
[12]	Bardia A, Hurvitz SA, Rugo HS, et al. A plain language summary of the ASCENT study: sacituzumab govitecan for metastatic triple-negative breast cancer[J]. Future Oncol, 2021, 17(30): 3911-3924. DOI: 10.2217/fon-2021-0868. doi: 10.2217/fon-2021-0868
[13]	Fleming PJ Jr, Karpio S, Lombardo N. Sacituzumab govitecan for treatment of refractory triple-negative metastatic breast cancer[J]. J Adv Pract Oncol, 2021, 12(7): 747-752. DOI: 10.6004/jadpro.2021.12.7.8. doi: 10.6004/jadpro.2021.12.7.8 pmid: 34671504
[14]	Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer[J]. Ann Transl Med, 2022, 10(7): 390. DOI: 10.21037/atm-22-484. doi: 10.21037/atm-22-484 pmid: 35530962
[15]	Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9): 1148-1156. DOI: 10.1016/j.annonc.2021.06.002. doi: 10.1016/j.annonc.2021.06.002 pmid: 34116144
[16]	Pavone G, Motta L, Martorana F, et al. A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors[J]. Molecules, 2021, 26(23): 7294. DOI: 10.3390/molecules26237294. doi: 10.3390/molecules26237294
[17]	O'Shaughnessy J, Brufsky A, Rugo HS, et al. 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase Ⅲ ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)[J]. Ann Oncol, 2021, 32(Supplement 5): S473-S474. DOI: 10.1016/j.annonc.2021.08.541. doi: 10.1016/j.annonc.2021.08.541
[18]	O'Shaughnessy J, Brufsky A, Rugo HS, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. Breast Cancer Res Treat, 2022, 195(2): 127-139. DOI: 10.1007/s10549-022-06602-7. doi: 10.1007/s10549-022-06602-7
[19]	Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): four design features in the ASCENT trial potentially favored the experimental arm[J]. Transl Oncol, 2022, 15(1): 101248. DOI: 10.1016/j.tranon.2021.101248. doi: 10.1016/j.tranon.2021.101248
[20]	Rugo HS, Tolaney SM, Loirat D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 98. DOI: 10.1038/s41523-022-00467-1. doi: 10.1038/s41523-022-00467-1 pmid: 36038616
[21]	Loibl S, Loirat D, Tolaney SM, et al. 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2021, 32(Supplement 5): S472-S473. DOI: 10.1016/j.annonc.2021.08.540. doi: 10.1016/j.annonc.2021.08.540
[22]	Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics[J]. Cancer, 2017, 123(19): 3843-3854. DOI: 10.1002/cncr.30789. doi: 10.1002/cncr.30789 pmid: 28558150
[23]	Drugs. com. Trodelvy[EB/OL]. [2022-06-01] [2022-09-06]. https://www.drugs.com/pro/trodelvy.html.
[24]	Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update[J]. J Clin Oncol, 2020, 38(24): 2782-2797. DOI: 10.1200/JCO.20.01296. doi: 10.1200/JCO.20.01296 pmid: 32658626
[25]	Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities[J]. Oncologist, 2021, 26(10): 827-834. DOI: 10.1002/onco.13878. doi: 10.1002/onco.13878
[26]	Spring L, Tolaney SM, Desai NV, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial[J]. J Clin Oncol, 2022, 40(16_suppl): 512. DOI: 10.1200/JCO.2022.40.16_suppl.512. doi: 10.1200/JCO.2022.40.16_suppl.512
[27]	Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR⁺/HER2^-) advanced breast cancer[J]. J Clin Oncol, 2022, 40(17_suppl): LBA1001. DOI: 10.1200/JCO.2022.40.17_suppl.LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
[28]	ClinicalTrials.gov. Sacituzumab govitecan in primary HER2-negative breast cancer (SASCIA)[EB/OL]. [2022-04-20] [2022-09-06]. https://clinicaltrials.gov/ct2/show/record/NCT04595565.
[29]	ClinicalTrials.gov. A study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced triple-negative breast cancer (Morpheus-TNBC)[EB/OL]. [2022-10-18] [2022-09-06]. https://clinicaltrials.gov/ct2/show/record/NCT03424005.
[30]	ClinicalTrials.gov. Sacituzumab govitecan +/- pembrolizumab in metastatic TNBC[EB/OL]. [2022-03-16] [2022-09-06]. https://clinicaltrials.gov/ct2/show/NCT04468061.
[31]	ClinicalTrials.gov. Study to evaluate sacituzumab govitecan in combination with talazoparib in patients with metastatic breast cancer[EB/OL]. [2021-10-27] [2022-09-06]. https://www.clinicaltrials.gov/ct2/show/NCT04039230.
[32]	Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer[J]. Cancer Discov, 2021, 11(10): 2436-2445. DOI: 10.1158/2159-8290.CD-21-0702. doi: 10.1158/2159-8290.CD-21-0702 pmid: 34404686